Westbourne Investment Advisors Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 12.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,482 shares of the company’s stock after purchasing an additional 2,302 shares during the quarter. Johnson & Johnson comprises about 2.3% of Westbourne Investment Advisors Inc.’s holdings, making the stock its 10th biggest position. Westbourne Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $2,643,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently bought and sold shares of the business. Intl Fcstone Inc. grew its stake in Johnson & Johnson by 13.3% during the third quarter. Intl Fcstone Inc. now owns 5,311 shares of the company’s stock valued at $734,000 after acquiring an additional 625 shares in the last quarter. Cahaba Wealth Management Inc. bought a new stake in Johnson & Johnson during the 3rd quarter valued at $216,000. BTR Capital Management Inc. raised its holdings in Johnson & Johnson by 3.7% in the 3rd quarter. BTR Capital Management Inc. now owns 99,668 shares of the company’s stock worth $13,771,000 after purchasing an additional 3,516 shares in the last quarter. Benson Investment Management Company Inc. raised its holdings in Johnson & Johnson by 4.1% in the 3rd quarter. Benson Investment Management Company Inc. now owns 23,323 shares of the company’s stock worth $3,223,000 after purchasing an additional 925 shares in the last quarter. Finally, Cibc Bank USA grew its position in shares of Johnson & Johnson by 4.5% in the 3rd quarter. Cibc Bank USA now owns 22,640 shares of the company’s stock worth $3,129,000 after buying an additional 967 shares during the period. Institutional investors and hedge funds own 67.20% of the company’s stock.
JNJ has been the topic of a number of recent analyst reports. Raymond James raised their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Wells Fargo & Co reiterated an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a research report on Wednesday, March 27th. Finally, Barclays reiterated an “equal weight” rating and set a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $146.90.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. Johnson & Johnson’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.06 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.73%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date of this dividend is Friday, May 24th. Johnson & Johnson’s payout ratio is presently 44.01%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.